|
Pfizer, Inc.
235 E 42nd St, New York, NY 10017 www.Pfizer.com About Pfizer At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. Representatives
Corey Stern Account Specialist Dermatology (215) 589-5925 corey.stern@pfizer.com Julie Riley Account Specialist Dermatology (610) 653-9970 julie.riley@pfizer.com Scott Osmers Account Specialist Dermatology (215) 813-0703 scott.osmers@pfizer.com Mike Vitti Account Specialist Dermatology (717) 368-8242 michael.vitti@pfizer.com Sara Kinney Account Specialist Dermatology (215) 802-7149 sara.meenan@pfizer.com Susan Ratner Account Specialist Dermatology (412) 478-1660 susan.rattner@pfizer.com Leigh Butler Account Specialist Dermatology (814) 883-4247 leigh.butler@pfizer.com Brian Hennigan Account Specialist Dermatology (724) 255-4677 brian.hennigan@pfizer.com |
EUCRISA
www.eucrisahcp.com INDICATION
EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. IMPORTANT SAFETY INFORMATION Contraindications EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation. Warnings and Precautions Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur. Adverse Reactions The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging. |
